TWI832010B - Irak抑制劑及其製備方法和用途 - Google Patents

Irak抑制劑及其製備方法和用途 Download PDF

Info

Publication number
TWI832010B
TWI832010B TW109132989A TW109132989A TWI832010B TW I832010 B TWI832010 B TW I832010B TW 109132989 A TW109132989 A TW 109132989A TW 109132989 A TW109132989 A TW 109132989A TW I832010 B TWI832010 B TW I832010B
Authority
TW
Taiwan
Prior art keywords
compound
formula
group
acid
degrees celsius
Prior art date
Application number
TW109132989A
Other languages
English (en)
Chinese (zh)
Other versions
TW202115015A (zh
Inventor
野國中
丁陳利
丁雅雯
賀潜
王朝東
Original Assignee
大陸商上海美悦生物科技發展有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商上海美悦生物科技發展有限公司 filed Critical 大陸商上海美悦生物科技發展有限公司
Publication of TW202115015A publication Critical patent/TW202115015A/zh
Application granted granted Critical
Publication of TWI832010B publication Critical patent/TWI832010B/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW109132989A 2019-09-24 2020-09-23 Irak抑制劑及其製備方法和用途 TWI832010B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910906833.7 2019-09-24
CN201910906833 2019-09-24

Publications (2)

Publication Number Publication Date
TW202115015A TW202115015A (zh) 2021-04-16
TWI832010B true TWI832010B (zh) 2024-02-11

Family

ID=75165579

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109132989A TWI832010B (zh) 2019-09-24 2020-09-23 Irak抑制劑及其製備方法和用途

Country Status (23)

Country Link
US (1) US20220298139A1 (es)
EP (1) EP4015513B1 (es)
JP (1) JP7353474B2 (es)
KR (1) KR20220035450A (es)
CN (2) CN118146193A (es)
AU (1) AU2020352311B2 (es)
BR (1) BR112022001568A2 (es)
CA (1) CA3152167C (es)
CL (1) CL2022000725A1 (es)
CO (1) CO2022004978A2 (es)
DO (1) DOP2022000054A (es)
EC (1) ECSP22032016A (es)
ES (1) ES2967642T3 (es)
HR (1) HRP20240122T8 (es)
HU (1) HUE065288T2 (es)
IL (1) IL291158A (es)
LT (1) LT4015513T (es)
MX (1) MX2022003504A (es)
PE (1) PE20220944A1 (es)
PT (1) PT4015513T (es)
TW (1) TWI832010B (es)
WO (1) WO2021057785A1 (es)
ZA (1) ZA202204441B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230250064A1 (en) * 2020-06-23 2023-08-10 Shanghai Meiyue Biotech Development Co., Ltd. Preparation method for fused pyrazole-type compound
EP4310080A1 (en) * 2021-03-19 2024-01-24 Shanghai Meiyue Biotech Development Co., Ltd. Polymorphic forms of compound and preparation method therefor and application thereof
JP7555519B2 (ja) 2022-02-14 2024-09-24 アストラゼネカ・アクチエボラーグ Irak4阻害剤
CN114404415A (zh) 2022-02-25 2022-04-29 上海美悦生物科技发展有限公司 吲唑类化合物用于治疗银屑病的用途
CN115252609B (zh) * 2022-08-01 2023-05-26 上海美悦生物科技发展有限公司 一种irak4抑制剂的组合物及其制备方法、用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201725202A (zh) * 2015-12-22 2017-07-16 拜耳製藥公司 新穎經取代吲唑、其製法、包含其之醫藥製劑及其製備藥劑之用途
WO2017207385A1 (de) * 2016-05-31 2017-12-07 Bayer Pharma Aktiengesellschaft Substituierte 3-methylindazole, verfahren zu ihrer herstellung, pharmazeutische präparate, die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9202022A (es) * 1991-05-01 1992-11-01 Otsuka Pharma Co Ltd Derivados de pirazina y proceso para su preparacion.
EP2922840B1 (en) * 2012-11-08 2016-12-21 Bristol-Myers Squibb Company Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators
TWI667233B (zh) * 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺,其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
JO3705B1 (ar) * 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
UY36660A (es) * 2015-04-30 2016-11-30 Bayer Pharma AG Combinaciones de inhibidores de irak4
US10435396B2 (en) * 2016-03-03 2019-10-08 Bayer Pharma Aktiegesellschaft 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs
JP7004677B2 (ja) * 2016-06-01 2022-01-21 バイエル・アニマル・ヘルス・ゲーエムベーハー 動物におけるアレルギー性および/または炎症性疾患の治療および予防に有用な置換インダゾール
AU2018359248B2 (en) * 2017-10-31 2023-06-01 Curis, Inc. Compounds and compositions for treating hematological disorders
IL315310A (en) * 2017-12-26 2024-10-01 Kymera Therapeutics Inc IRAK joints and used in them
EP3889150A4 (en) * 2018-12-25 2022-02-23 Shanghai Meiyue Biotech Development Co., Ltd. IRAQ INHIBITOR COMPOUND
CN111499612B (zh) * 2019-01-30 2022-12-30 上海美悦生物科技发展有限公司 一种作为irak抑制剂的化合物及其制备方法和用途
US20230250064A1 (en) * 2020-06-23 2023-08-10 Shanghai Meiyue Biotech Development Co., Ltd. Preparation method for fused pyrazole-type compound

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201725202A (zh) * 2015-12-22 2017-07-16 拜耳製藥公司 新穎經取代吲唑、其製法、包含其之醫藥製劑及其製備藥劑之用途
WO2017207385A1 (de) * 2016-05-31 2017-12-07 Bayer Pharma Aktiengesellschaft Substituierte 3-methylindazole, verfahren zu ihrer herstellung, pharmazeutische präparate, die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln

Also Published As

Publication number Publication date
CA3152167A1 (en) 2021-04-01
JP7353474B2 (ja) 2023-09-29
CO2022004978A2 (es) 2022-04-29
DOP2022000054A (es) 2022-07-15
EP4015513A1 (en) 2022-06-22
HUE065288T2 (hu) 2024-05-28
CN118146193A (zh) 2024-06-07
ECSP22032016A (es) 2022-05-31
ZA202204441B (en) 2022-11-30
JP2022549870A (ja) 2022-11-29
PT4015513T (pt) 2023-12-19
TW202115015A (zh) 2021-04-16
AU2020352311B2 (en) 2023-11-09
US20220298139A1 (en) 2022-09-22
CA3152167C (en) 2023-12-19
MX2022003504A (es) 2022-07-19
HRP20240122T1 (hr) 2024-04-12
CL2022000725A1 (es) 2022-11-18
AU2020352311A1 (en) 2022-04-14
HRP20240122T8 (hr) 2024-05-24
BR112022001568A2 (pt) 2022-03-22
EP4015513A4 (en) 2022-09-14
PE20220944A1 (es) 2022-05-31
WO2021057785A1 (zh) 2021-04-01
IL291158A (en) 2022-05-01
ES2967642T3 (es) 2024-05-03
CN114391013A (zh) 2022-04-22
KR20220035450A (ko) 2022-03-22
LT4015513T (lt) 2023-12-11
CN114391013B (zh) 2024-01-26
EP4015513B1 (en) 2023-11-01

Similar Documents

Publication Publication Date Title
TWI832010B (zh) Irak抑制劑及其製備方法和用途
TWI758300B (zh) 免疫調節劑化合物
JP6871864B2 (ja) イソオキサゾリル置換ベンズイミダゾール類
SA518391218B1 (ar) مثبطات أيزو إندولينون لتفاعل mdm2-p53 ذات نشاط مضاد للسرطان
KR20180094938A (ko) 오피오이드 수용체 리간드와 시토크롬 p450 억제제의 결합
WO2020035020A1 (zh) 咪唑并吡啶类衍生物及其制备方法和其在医药上的用途
HUE026170T2 (en) Substituted nicotinamides as modulators of KCNQ2 / 3
CN111560012B (zh) 一种作为irak抑制剂的化合物
ES2973714T3 (es) Bencimidazoles sustituidos como inhibidores de PAD4
CN111499612B (zh) 一种作为irak抑制剂的化合物及其制备方法和用途
CN114555080A (zh) 用于治疗pd-l1疾病的杂芳基联苯胺
CN111793064B (zh) 一种作为irak抑制剂的化合物及其制备方法和用途
JP2011506362A (ja) 2−アリールチアゾール−4−カルボキサミド誘導体、それらの製造および医薬としての使用
TWI671302B (zh) 具有吲哚胺2,3-雙加氧酶抑制活性的稠合咪唑化合物
WO2020057604A1 (zh) Tlr8激动剂
JP2011506358A (ja) 新規2−置換チアゾール−4−カルボキサミド誘導体、それらの製造および医薬としての使用
TW321647B (es)
AU2022271550A1 (en) Acid addition salt of rock inhibitor, and crystal form, composition and pharmaceutical use thereof
EP4155304A1 (en) Compound used as ret kinase inhibitor and application thereof
EA044151B1 (ru) Ингибитор irak и способ его получения и применения
CN110467629A (zh) 苯醌衍生物、其药物组合物及应用
WO2006123639A1 (ja) ピリミジン誘導体
EP4385976A1 (en) Substituted isoindolin-1,3-dione pde4 inhibitor and pharmaceutical use thereof
CN118063464A (zh) 一种pin1抑制剂及其在制备药物中的用途
WO2021051827A1 (zh) 一种细胞凋亡蛋白抑制剂及其制备方法和用途